Tirzepatide May Be More Effective For Weight Loss Than Semaglutide

Overweight or obese adults with type 2 diabetes who were treated with tirzepatide (Mounjaro) lost more weight than those who were treated with semaglutide (Ozempic). In a comparison of weight loss by drug type that included 18,386 participants taking one of the two drugs, most experienced 5% or greater weight loss, but the benefit was greater with tirzepatide. The discontinuation rate was higher among those receiving tirzepatide (55.9%) than semaglutide (52.5%).

Those receiving tirzepatide were 76% more likely to achieve weight loss of more than 5%, 154% more likely to achieve weight loss of more than 10 . . .